Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Obesity

Free Subscription Articles published in Lancet Retrieve available abstracts of 74 articles: HTML format

Single Articles

December 2026
1. HAY SI, Ng M, Gakidou E, Murray CJL, et al
   The need for metabolic health stratification in global obesity forecasts - Authors' reply.
   Lancet. 2026;406:2923-2924.
   PubMed    
   
   
   
2. FAUCHIER L, Guglieri M, Fauchier G
   The need for metabolic health stratification in global obesity forecasts.
   Lancet. 2026;406:2923.
   PubMed    
   
   
   
3. CHOW EW, Chow E
   Oral small-molecule GLP-1 receptor agonist for type 2 diabetes and obesity.
   Lancet. 2026;406:2866-2868.
   PubMed    
   
   
   
4. MUSKIET MHA, Nardone M, Rensen PCN, Cherney DZI, et al
   Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?
   Lancet. 2026;406:2980-2983.
   PubMed     Abstract available
   
   
   July 2026
5. LU Y
   Convergence of metabolic risk in obesity and normal BMI: does risk disappear?
   Lancet. 2026 Jul 1:S0140-6736(26)01245-6. doi: 10.1016/S0140-6736(26)01245.
   PubMed    
   
   
   
6. 
   Metabolic traits in obesity and normal BMI in industrialised countries: a multi-country analysis of national population-based studies.
   Lancet. 2026 Jul 1:S0140-6736(26)00758-0. doi: 10.1016/S0140-6736(26)00758.
   PubMed     Abstract available
   
   
   June 2026
7. PARAJE G, Valdes N, Macaya AV, Corvalan C, et al
   The impact of Chile's multipronged food labelling and advertising law on early childhood excess weight: a cohort difference-in-differences study.
   Lancet. 2026;407:2630-2640.
   PubMed     Abstract available
   
   
   
8. PETTIGREW S, Coyle D
   Integrated food policy and child obesity.
   Lancet. 2026 Jun 11:S0140-6736(26)00915-3. doi: 10.1016/S0140-6736(26)00915.
   PubMed    
   
   
   
9. DAVIES MJ, Aroda VR, Rosenstock J, Capehorn M, et al
   Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial.
   Lancet. 2026 Jun 8:S0140-6736(26)00748-8. doi: 10.1016/S0140-6736(26)00748.
   PubMed     Abstract available
   
   
   May 2026
10. HORN DB, Aronne LJ, Wharton S, Bays HE, et al
    Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial.
    Lancet. 2026 May 12:S0140-6736(26)00656-2. doi: 10.1016/S0140-6736(26)00656.
    PubMed     Abstract available
    
    
    
11. KLAUSEN MK, Justesen SK, Pedersen JN, Rasmussen L, et al
    Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial.
    Lancet. 2026;407:1687-1698.
    PubMed     Abstract available
    
    
    March 2026
12. THE LANCET
    Making treatment for obesity more equitable.
    Lancet. 2026;407:1119.
    PubMed    
    
    
    
13. COUSINS S
    The boom in counterfeit obesity drugs.
    Lancet. 2026 Mar 5:S0140-6736(26)00461-7. doi: 10.1016/S0140-6736(26)00461.
    PubMed    
    
    
    February 2026
14. NYBERG ST, Frank P, Ahmadi-Abhari S, Pentti J, et al
    Adult obesity and risk of severe infections: a multicohort study with global burden estimates.
    Lancet. 2026 Feb 9:S0140-6736(25)02474-2. doi: 10.1016/S0140-6736(25)02474.
    PubMed     Abstract available
    
    
    
15. SORENSEN TIA, Osler M
    Mutually reinforced burdens of obesity and infections.
    Lancet. 2026 Feb 9:S0140-6736(25)02605-4. doi: 10.1016/S0140-6736(25)02605.
    PubMed    
    
    
    January 2026
16. NAUCK MA, Tuttle KR, Tschop MH, Bluher M, et al
    Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits.
    Lancet. 2026 Jan 14:S0140-6736(25)02105-1. doi: 10.1016/S0140-6736(25)02105.
    PubMed     Abstract available
    
    
    November 2025
17. HORN DB, Ryan DH, Kis SG, Alves B, et al
    Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.
    Lancet. 2025 Nov 20:S0140-6736(25)02165-8. doi: 10.1016/S0140-6736(25)02165.
    PubMed     Abstract available
    
    
    
18. BILLINGS LK, Hsia S, Bays H, Tidemann-Miller B, et al
    Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial.
    Lancet. 2025 Nov 6:S0140-6736(25)02155-5. doi: 10.1016/S0140-6736(25)02155.
    PubMed     Abstract available
    
    
    October 2025
19. DEANFIELD J, Lincoff AM, Kahn SE, Emerson SS, et al
    Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial.
    Lancet. 2025 Oct 22:S0140-6736(25)01375-3. doi: 10.1016/S0140-6736(25)01375.
    PubMed     Abstract available
    
    
    September 2025
20. THE LANCET
    Childhood obesity: a global health crisis.
    Lancet. 2025;406:1193.
    PubMed    
    
    
    
21. HUNTER KE, Nguyen D, Libesman S, Williams JG, et al
    Parent-focused behavioural interventions for the prevention of early childhood obesity (TOPCHILD): a systematic review and individual participant data meta-analysis.
    Lancet. 2025 Sep 10:S0140-6736(25)01144-4. doi: 10.1016/S0140-6736(25)01144.
    PubMed     Abstract available
    
    
    August 2025
22. ROBERT M, Poghosyan T, Romain-Scelle N, Czernichow S, et al
    Efficacy and safety of single-anastomosis duodeno-ileal bypass with sleeve gastrectomy versus Roux-en-Y gastric bypass in France (SADISLEEVE): results of a randomised, open-label, superiority trial at 2 years of follow-up.
    Lancet. 2025;406:846-859.
    PubMed     Abstract available
    
    
    
23. ELLS LJ, Homer C, Matu J, Aswani D, et al
    Compassionate child obesity care within a stigmatising society.
    Lancet. 2025;406:444.
    PubMed    
    
    
    July 2025
24. DAHL K, Toubro S, Dey S, Duque do Vale R, et al
    Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.
    Lancet. 2025;406:149-162.
    PubMed     Abstract available
    
    
    
25. GASIOREK A, Heydorn A, Gabery S, Hjerpsted JB, et al
    Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial.
    Lancet. 2025;406:135-148.
    PubMed     Abstract available
    
    
    June 2025
26. KHOO B, Tan TM
    GLP-1 and amylin receptor multiagonism with amycretin for obesity management.
    Lancet. 2025 Jun 20:S0140-6736(25)01250-4. doi: 10.1016/S0140-6736(25)01250.
    PubMed    
    
    
    
27. LUK A, Wild SH, Jones S, Anjana RM, et al
    Early-onset type 2 diabetes: the next major diabetes transition.
    Lancet. 2025 Jun 20:S0140-6736(25)00830-X. doi: 10.1016/S0140-6736(25)00830.
    PubMed     Abstract available
    
    
    February 2025
28. 
    Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021.
    Lancet. 2025 Feb 28:S0140-6736(25)00355-1. doi: 10.1016/S0140-6736(25)00355.
    PubMed     Abstract available
    
    
    
29. 
    Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021.
    Lancet. 2025 Feb 28:S0140-6736(25)00397-6. doi: 10.1016/S0140-6736(25)00397.
    PubMed     Abstract available
    
    
    
30. SORENSEN TIA
    Forecasting the global obesity epidemic through 2050.
    Lancet. 2025 Feb 28:S0140-6736(25)00260-0. doi: 10.1016/S0140-6736(25)00260.
    PubMed    
    
    
    January 2025
31. HORTON R
    Offline: Making obesity matter.
    Lancet. 2025;405:284.
    PubMed    
    
    
    
32. KLOPPENBURG M, Namane M, Cicuttini F
    Osteoarthritis.
    Lancet. 2025;405:71-85.
    PubMed     Abstract available
    
    
    November 2024
33. KIRBY T
    Brazil considers obesity discrimination law.
    Lancet. 2024;404:1912-1913.
    PubMed    
    
    
    
34. SEBERT S
    The obesity crisis in the USA: why are there no signs of plateauing yet?
    Lancet. 2024 Nov 12:S0140-6736(24)02467-X. doi: 10.1016/S0140-6736(24)02467.
    PubMed    
    
    
    
35. 
    National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990-2021, and forecasts up to 2050.
    Lancet. 2024 Nov 12:S0140-6736(24)01548-4. doi: 10.1016/S0140-6736(24)01548.
    PubMed     Abstract available
    
    
    October 2024
36. EZZATI M, Zhou B, Bennett JE, Phelps NH, et al
    Assessing worldwide trends of underweight and obesity - Authors' reply.
    Lancet. 2024;404:1644.
    PubMed    
    
    
    
37. BOMBAK A, Riediger N
    Assessing worldwide trends of underweight and obesity.
    Lancet. 2024;404:1643.
    PubMed    
    
    
    
38. CHRISTENSEN DL, Bygbjerg IC
    Assessing worldwide trends of underweight and obesity.
    Lancet. 2024;404:1642.
    PubMed    
    
    
    
39. CZERNICHOW S, Ziegler O, Clement K, Coupaye M, et al
    Assessing worldwide trends of underweight and obesity.
    Lancet. 2024;404:1642-1643.
    PubMed    
    
    
    
40. VAN STEIJVOORT E, Borry P
    Assessing worldwide trends of underweight and obesity.
    Lancet. 2024;404:1641-1642.
    PubMed    
    
    
    August 2024
41. 
    General and abdominal adiposity and hypertension in eight world regions: a pooled analysis of 837 population-based studies with 7.5 million participants.
    Lancet. 2024;404:851-863.
    PubMed     Abstract available
    
    
    
42. NASIR K
    Embracing the duality of BMI and central adiposity.
    Lancet. 2024;404:824-825.
    PubMed    
    
    
    
43. KOSIBOROD MN, Deanfield J, Pratley R, Borlaug BA, et al
    Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.
    Lancet. 2024 Aug 29:S0140-6736(24)01643-X. doi: 10.1016/S0140-6736(24)01643.
    PubMed     Abstract available
    
    
    
44. DEANFIELD J, Verma S, Scirica BM, Kahn SE, et al
    Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.
    Lancet. 2024;404:773-786.
    PubMed     Abstract available
    
    
    
45. LINGVAY I, Cohen RV, Roux CWL, Sumithran P, et al
    Obesity in adults.
    Lancet. 2024 Aug 16:S0140-6736(24)01210-8. doi: 10.1016/S0140-6736(24)01210.
    PubMed     Abstract available
    
    
    May 2024
46. MORIN-PAPUNEN L
    Bariatric surgery in women with PCOS and obesity.
    Lancet. 2024 May 20:S0140-6736(24)00811-0. doi: 10.1016/S0140-6736(24)00811.
    PubMed    
    
    
    
47. SAMARASINGHE SNS, Leca B, Alabdulkader S, Dimitriadis GK, et al
    Bariatric surgery for spontaneous ovulation in women living with polycystic ovary syndrome: the BAMBINI multicentre, open-label, randomised controlled trial.
    Lancet. 2024 May 20:S0140-6736(24)00538-5. doi: 10.1016/S0140-6736(24)00538.
    PubMed     Abstract available
    
    
    April 2024
48. THE LANCET EDITORS
    Retraction and republication-Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.
    Lancet. 2024;403:1321.
    PubMed    
    
    
    
49. SHI Q, Wang Y, Hao Q, Vandvik PO, et al
    Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.
    Lancet. 2024;403:e21-e31.
    PubMed     Abstract available
    
    
    
50. BUTLER J, Shah SJ, Petrie MC, Borlaug BA, et al
    Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.
    Lancet. 2024 Apr 4:S0140-6736(24)00469-0. doi: 10.1016/S0140-6736(24)00469.
    PubMed     Abstract available
    
    
    
51. DONAL E, L'Official G, Istratoaie S
    Semaglutide-a new treatment for obesity-related heart failure with preserved ejection fraction?
    Lancet. 2024 Apr 4:S0140-6736(24)00653-6. doi: 10.1016/S0140-6736(24)00653.
    PubMed    
    
    
    March 2024
52. JOHANSSON K, Bodnar LM, Stephansson O, Abrams B, et al
    Safety of low weight gain or weight loss in pregnancies with class 1, 2, and 3 obesity: a population-based cohort study.
    Lancet. 2024 Mar 28:S0140-6736(24)00255-1. doi: 10.1016/S0140-6736(24)00255.
    PubMed     Abstract available
    
    
    
53. GAILLARD R
    Optimising gestational weight gain among pregnant women with obesity.
    Lancet. 2024 Mar 28:S0140-6736(24)00470-7. doi: 10.1016/S0140-6736(24)00470.
    PubMed    
    
    
    February 2024
54. TUMAS N, Lopez SR
    Double burden of underweight and obesity: insights from new global evidence.
    Lancet. 2024 Feb 29:S0140-6736(24)00051-5. doi: 10.1016/S0140-6736(24)00051.
    PubMed    
    
    
    
55. 
    Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults.
    Lancet. 2024 Feb 29:S0140-6736(23)02750-2. doi: 10.1016/S0140-6736(23)02750.
    PubMed     Abstract available
    
    
    
56. CAMPBELL P, Rutten FH, Lee MM, Hawkins NM, et al
    Heart failure with preserved ejection fraction: everything the clinician needs to know.
    Lancet. 2024 Feb 14:S0140-6736(23)02756-3. doi: 10.1016/S0140-6736(23)02756.
    PubMed     Abstract available
    
    
    January 2024
57. THE LANCET
    Treating obesity and diabetes: drugs alone are not enough.
    Lancet. 2024;403:1.
    PubMed    
    
    
    December 2023
58. DANIELS JP
    Colombia introduces junk food tax.
    Lancet. 2023;402:2062.
    PubMed    
    
    
    November 2023
59. ZOU M, Northstone K, Leary S
    Causal effects of later-eating rhythm on adiposity in children through the comparison of two cohorts in the UK and China: a cross-cohort study.
    Lancet. 2023;402 Suppl 1:S99.
    PubMed     Abstract available
    
    
    
60. ALRUBAIAN F, Mulla Z
    Governments policy measures to address obesity among adults: a scoping review of the global evidence.
    Lancet. 2023;402 Suppl 1:S20.
    PubMed     Abstract available
    
    
    
61. CISNEROS AB, Headings R, Wells R, Reynolds C, et al
    Understanding the use of media analysis in public health research through food tax debates (HEALTHEI Project): a scoping review.
    Lancet. 2023;402 Suppl 1:S9.
    PubMed     Abstract available
    
    
    
62. SPAVIN A, Moore A, Lunn J, Tucker F, et al
    Reflecting on parental insights into healthy lifestyles: a qualitative study.
    Lancet. 2023;402 Suppl 1:S85.
    PubMed     Abstract available
    
    
    
63. CHEN S, Kuper H
    Tracing the temporal trends of modifiable risk factors in dementia: insights from the English Longitudinal Study of Ageing (2004-2019).
    Lancet. 2023;402 Suppl 1:S34.
    PubMed     Abstract available
    
    
    
64. WALSH S, Wallace L, Kuhn I, Mytton O, et al
    Population-level interventions for the primary prevention of dementia: a complex evidence review.
    Lancet. 2023;402 Suppl 1:S13.
    PubMed     Abstract available
    
    
    October 2023
65. KOTANI T, Tano S
    Long-term effects of gestational weight gain on mortality.
    Lancet. 2023 Oct 19:S0140-6736(23)01837-8. doi: 10.1016/S0140-6736(23)01837.
    PubMed    
    
    
    
66. HINKLE SN, Mumford SL, Grantz KL, Mendola P, et al
    Gestational weight change in a diverse pregnancy cohort and mortality over 50 years: a prospective observational cohort study.
    Lancet. 2023 Oct 19:S0140-6736(23)01517-9. doi: 10.1016/S0140-6736(23)01517.
    PubMed     Abstract available
    
    
    September 2023
67. SUMITHRAN P, Finucane FM, Cohen RV
    Obesity drug shortages are symptomatic of wider malaise.
    Lancet. 2023 Sep 29:S0140-6736(23)01963-3. doi: 10.1016/S0140-6736(23)01963.
    PubMed    
    
    
    June 2023
68. GARVEY WT, Frias JP, Jastreboff AM, le Roux CW, et al
    Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
    Lancet. 2023 Jun 26:S0140-6736(23)01200-X. doi: 10.1016/S0140-6736(23)01200.
    PubMed     Abstract available
    
    
    
69. APOVIAN CM, McDonnell ME
    CagriSema and the link between obesity and type 2 diabetes.
    Lancet. 2023 Jun 23:S0140-6736(23)01291-6. doi: 10.1016/S0140-6736(23)01291.
    PubMed    
    
    
    
70. KNOP FK, Aroda VR, do Vale RD, Holst-Hansen T, et al
    Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2023 Jun 23:S0140-6736(23)01185-6. doi: 10.1016/S0140-6736(23)01185.
    PubMed     Abstract available
    
    
    
71. FALLOWS E, Ells L, Anand V
    Semaglutide and the future of obesity care in the UK.
    Lancet. 2023 Jun 5:S0140-6736(23)01083-8. doi: 10.1016/S0140-6736(23)01083.
    PubMed    
    
    
    May 2023
72. SKYLE D
    Fatima Cody Stanford: changing the narrative on obesity.
    Lancet. 2023;401:1644.
    PubMed    
    
    
    April 2023
73. MAHGOUB S, Newsome PN
    Bariatric-metabolic surgery versus lifestyle intervention in non-alcoholic steatohepatitis.
    Lancet. 2023 Apr 20:S0140-6736(23)00773-0. doi: 10.1016/S0140-6736(23)00773.
    PubMed    
    
    
    
74. VERRASTRO O, Panunzi S, Castagneto-Gissey L, De Gaetano A, et al
    Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial.
    Lancet. 2023 Apr 20:S0140-6736(23)00634-7. doi: 10.1016/S0140-6736(23)00634.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Obesity is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum